Relenza Studies In High-Risk Populations Might Show More Efficacy - Cmte.
Executive Summary
Additional studies of Glaxo Wellcome's Relenza Diskhaler should be targeted to specific high-risk populations in order to more clearly show efficacy of zanamivir against influenza, members of FDA's Antiviral Drugs Advisory Committee said Feb. 24.
You may also be interested in...
Relenza Growth Will Rely On Prophylaxis Use; Flovent Flies In U.S., Up 55%
A Relenza prophylaxis indication is key to the future growth of the inhaled neuraminidase inhibitor, Glaxo Wellcome Chairman Richard Sykes said July 27 at a half-year results meeting in London.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011